The industry’s leading scalable electroporation technology for high yield transient expression of complex proteins, vaccines and biologics.
- Rapidly transfect from 75 thousand to 20 billion cells
- High efficiency with flexible media strategies deliver significant cost savings
- Improved yields, at scale, can decrease development timelines
- Proprietary Flow Electroporation™ Technology
- Faster production of stable clones
- ISO-certified, and CE-marked